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Abstract: Lack of sensitive diagnostic tests impairs the understanding of the epidemiology of
histoplasmosis, a disease whose burden is estimated to be largely underrated. Broad-range PCRs have
been applied to identify fungal agents from pathology blocks, but sensitivity is variable. In this study,
we compared the results of a specific Histoplasma qPCR (H. qPCR) with the results of a broad-range
qPCR (28S qPCR) on formalin-fixed, paraffin-embedded (FFPE) tissue specimens from patients with
proven fungal infections (n = 67), histologically suggestive of histoplasmosis (n = 36) and other
mycoses (n = 31). The clinical sensitivity for histoplasmosis of the H. qPCR and the 28S qPCR was
94% and 48.5%, respectively. Samples suggestive for other fungal infections were negative with
the H. qPCR. The 28S qPCR did not amplify DNA of Histoplasma in FFPE in these samples, but
could amplify DNA of Emergomyces (n = 1) and Paracoccidioides (n = 2) in three samples suggestive
for histoplasmosis but negative in the H. qPCR. In conclusion, amplification of Histoplasma DNA
from FFPE samples is more sensitive with the H. qPCR than with the 28S qPCR. However, the 28S
qPCR identified DNA of other fungi in H. qPCR-negative samples presenting like histoplasmosis,
suggesting that the combination of both assays may improve the diagnosis.
Keywords: Histoplasma qPCR; broad-range qPCR; formalin-fixed paraffin-embedded (FFPE)
samples; histoplasmosis
1. Introduction
While histoplasmosis is a reportable disease in several states of the USA, estimates of the global
burden are difficult. Reports from South and Central America and the Caribbean suggest that
histoplasmosis is an important acquired immune deficiency syndrome (AIDS)-defining infection and a
major killer of human immunodeficiency virus (HIV)-infected patients [1–8]. The mortality rate of
HIV-associated histoplasmosis is estimated to be equal to or even higher than for tuberculosis [8–10].
In a recent report reviewing 470 published histoplasmosis cases from Africa between 1952 and 2007, the
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authors concluded that the prevalence of histoplasmosis may be underestimated, as a large proportion
of disseminated cases may be misdiagnosed as culture-negative tuberculosis [11].
The diagnosis of histoplasmosis is challenging due to an unspecific clinical presentation and
suboptimal diagnostic tests. Cultivation of Histoplasma remains the gold standard for the diagnosis
of histoplasmosis, but slow growth and low culture sensitivity reduce its usefulness [12]. In fact, the
sensitivity of cultures may vary from 26% to 58% depending on the clinical manifestation, the net
state of the immunity, and the severity of disease [13]. Antibody detection tests may be negative
during the first four to eight weeks, especially in patients with impaired humoral immunity [13].
Moreover, false-positive results are possible with other invasive fungal infections [13]. Still, Histoplasma
antigen testing could be a helpful tool in immunosuppressed patients with disseminated disease,
but its availability is limited in many countries [14,15]. Serum Aspergillus galactomannan, which is
widely available, has shown cross-reactivity with Histoplasma and may have some utility in detection
of disseminated histoplasmosis in patients with AIDS [16]. However, its utility is limited by the lack of
specificity [16].
Tissue biopsies are frequently necessary to confirm histoplasmosis, but cultures may remain
negative and the demonstration of small budding yeasts clustering in phagocytes by histopathology
is not pathognomonic [17]. For example, the recently described emergomycosis, or more prevalent
mycoses including candidiasis, could potentially be misdiagnosed as histoplasmosis [18]. Previously,
thorough microscopic examination of pathology blocks helped to document changes in the epidemiology
of invasive fungal infections, including the increases of mold infections such as mucormycosis [19,20].
Pathology blocks are stored in tissue archives and may provide a valuable resource to gain insights
into the epidemiology of histoplasmosis. In order to optimize the identification of fungal pathogens in
pathology blocks, broad-range PCRs have been applied but are limited by DNA degradation due to
fixation and contamination by fungal DNA [21,22].
In this study, we applied a qPCR specific for Histoplasma (H. qPCR) published in 2008 by
Simon et al. [23] that demonstrated a high sensitivity (95.4%) and specificity (96%) using 348 fresh
human samples from patients with high pretest probability for histoplasmosis. Interestingly, 11
culture-negative samples of proven histoplasmosis patients yielded positive results in the H. qPCR [23].
We compared the clinical sensitivity and specificity [24] of this H. qPCR on clinical FFPE samples
suggestive for histoplasmosis or other invasive fungal infection with results of a broad-range fungal
qPCR targeting the 28S ribosomal RNA gene (28S qPCR) to get insights into the best molecular strategy
to identify histoplasmosis from FFPE samples.
2. Materials and Methods
2.1. DNA Extractions and qPCR Amplification Conditions
For DNA extraction from FFPE specimens, aliquots of four 5 µm sections were placed in Eppendorf
Biopur® tubes (Eppendorf AG, Hamburg, Germany). One extraction-negative control, consisting
of DNA free water per three samples, was processed in parallel. The samples were deparaffinized
using octane. DNA was extracted using the Master Pure Yeast DNA Purification Kit (Epicentre
Biotechnologies, Madison, WI, USA) at 90 ◦C for 3 h with an additional bead-beating step to optimize
fungal cell lysis. After a protein precipitation step, the DNA was precipitated by isopropanol, washed
with 70% ethanol, and stored in 75 µL Triton X 0.1% at 4 ◦C for the short term (<7days) or at −20 ◦C for
the longer term [25].
Each of these DNAs was studied by four different qPCRs. To document successful DNA extraction,
a human DNA detecting qPCR [26] was used. An internal amplification control DNA (IAC qPCR)
was used to determine PCR inhibitory activities. Fungal DNA was amplified using a broad-range
28S qPCR and a specific qPCR assay to detect Histoplasma DNA [23,26]. The extraction-negative
controls were treated accordingly. All these qPCRs were performed on the 7500 Real-Time PCR
System (Applied Biosystems, Foster City, CA, USA). Samples were tested in single tubes in the human
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DNA-detecting qPCR and in the IAC qPCR for 40 cycles or in duplicates in the 28S qPCR and the
H. qPCR for 45 cycles. If inhibition (delta cycle threshold (CT) of more than 2 cycles) was detected and
fungal qPCRs remained negative, DNA was again purified from the protein precipitation step of the
extraction kit onwards in an attempt to remove the remaining PCR inhibitors [26].
The broad-range qPCR, targeting the ribosomal 28S rDNA genes (primer 10F and 12R), was
performed as elsewhere described [21,27]. Each PCR run included six to eight no-template controls
(NTC) and a standard curve ranging from 10 fg to 1 ng/reaction of C. albicans (ATCC 10231) DNA.
A positive broad-range qPCR was defined as amplification of a fungal DNA in duplicates in less than
40 CTs with identical peaks in the melting curve analysis (±1 ◦C) in the absence of positive no-template,
or extraction-negative controls. Amplicons of broad-range qPCR positive samples were sequenced.
Amplicons were identified by BLAST search in GenBank [28]. Sequence identity of 98% and more was
considered as the identification at genus level.
For the H. qPCR, targeting a region in the internal transcribed spacer 1 (ITS1) rDNA, the primers
and the TaqMan probe were used as described by Simon et al. [23]. The Master Mix was replaced
by TaqMan® Universal PCR Master Mix II with uracil-N-glycosylase (Thermo Fisher, Schwerte, GE,
Germany). Each run included four NTCs and a standard curve ranging from 10 fg to 1 ng/reaction
of Histoplasma DNA. In contrast to the original publication, each sample which attained any positive
result in the absence of positive NTCs and negative extraction controls was considered as positive.
2.2. Analytic Sensitivity and Specificity of the Histoplasma-Specific qPCR
For the determination of the analytical sensitivity and specificity, one clinical Histoplasma isolate
(RKI 12-0644), nineteen other fungal isolates, and a human DNA preparation (Roche Applied Sciences;
Cat. No. 11691112001, Indianapolis, IN, USA) were used (Table 1). Fungal strains were selected
considering the most important fungal pathogens and colonizers in humans. In addition, we included
fungi potentially mimicking histoplasmosis in histological samples.
Table 1. Strains and human genomic DNA used to confirm the analytical sensitivity and specificity of
the Histoplasma-specific qPCR.
Strains DNA Standardized at 100 pg/Reaction Origin Histoplasma qPCR Result
Aspergillus fumigatus ATCC 46645 negative
Blastomyces dermatitidis ATCC 18188 negative
Blastomyces percursus CBS 139878 negative
Candida albicans ATCC 10231 negative
Candida glabrata ATCC 64677 negative
Coccidioides immitis CBS 113856 negative
Coccidioides posadasii CBS 113859 negative
Cryptococcus gattii CBS 6289.85 negative
Cryptococcus neoformans H99 CBS 8710 negative
Cunninghamella bertholletiae RKI 99-0536 negative
Emergomyces africanus CBS 136260 negative
Emergomyces europaeus RKI 17-1077 negative
Emergomyces orientalis CBS 124587 negative
Emergomyces pasteurianus CBS 101426 negative
Emmonsia parva CBS 139881 negative
Exophiala dermatitidis CBS 748.88 negative
Histoplasma capsulatum RKI 12-0644 positive
Paracoccidioides brasiliensis ATCC MYA-826 negative
Talaromyces marneffei RKI 16-0774 negative
Trichophyton violaceum RKI 16-0839 negative
Human Genomic DNA Roche® Cat. No. 11 691 112 001 negative
ATCC: American Type Culture Collection; CBS: Centraalbureau voor schimmelcultures (now known as Westerdijk
Fungal Biodiversity Institute), Utrecht, Netherlands; RKI: strains isolated from fungal cultures derived from patient
samples at the Robert Koch Institute.
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For the calibration curve, the Histoplasma DNA was standardized at 1 ng/reaction and then serially
diluted 10-fold to obtain solutions ranging from 1 ng to 1 fg/reaction. The sensitivity threshold was
analyzed by running these DNA solutions on every H. qPCR run (in duplicates for the 1 fg/reaction
standard). The analytic sensitivity (LOD) was defined as the lowest concentration which could be
detected with a reasonable certainty (95%) [29]. Every positive test, even if only one of the duplicates
were positive, was interpreted as a positive result.
In order to screen for cross-amplification of nontarget DNA, DNA of other fungi and human DNA
were first standardized at 100 pg/reaction by the Qubit fluorometer using the dsDNA HS Assay Kit
(Thermo Fisher, Schwerte, GE, Germany) and by the 28S qPCR, and then tested in duplicates in the H.
qPCR. The identity of the strains was confirmed by sequencing the ITS region and PCR inhibition of the
DNA standards was excluded by testing an internal amplification control (IAC) via qPCR. Inhibition
was defined as a delta CT of more than 2 cycles.
2.3. Clinical Sensitivity and Specificity
FFPE tissue samples were cut into 5 µm thick sections. The first and the last sections were placed on
slides and stained by Grocott’s methenamine silver stain (GMS) with Hematoxylin Eosin or Lightgreen
counterstain. For each sample, these two slides were examined under the microscope for fungal elements.
For the analysis of the clinical sensitivity and specificity [24], FFPE tissue samples from patients with
histologically proven invasive fungal infection were used [30]. A total of 36 specimens (human n = 29
from 22 patients; animal n = 7 from 4 animals; one badger and three cats) suggestive for histoplasmosis
defined by demonstration of small yeast cells (2–4 µm in size) with narrow-based budding, especially
when grouped in clusters inside macrophages, were included (Table 2 and Figure 1) [17]. Subsequently,
three of these samples were excluded from this analysis, as the 28S qPCR suggested an alternative
diagnosis (samples 34–36).
Table 2. Formalin-fixed, paraffin-embedded tissue samples used for the determination of the clinical










1 a skin histoplasmosis Histoplasma capsulatum positive
2 a skin histoplasmosis Histoplasma capsulatum positive
3 a mucosa histoplasmosis Histoplasma capsulatum positive
4 a, b skin histoplasmosis Histoplasma capsulatum positive
5 vocal fold histoplasmosis Histoplasma capsulatum positive
6 lung histoplasmosis Histoplasma capsulatum positive
7 lymph node histoplasmosis Histoplasma capsulatum positive
8 adrenal gland histoplasmosis Histoplasma capsulatum positive
9 esophagus histoplasmosis Histoplasma capsulatum positive
10 duodenum histoplasmosis Histoplasma capsulatum positive
11 lung histoplasmosis Histoplasma capsulatum positive
12 lung histoplasmosis Histoplasma capsulatum positive
13 lung histoplasmosis Histoplasma capsulatum positive
14 intestine histoplasmosis Histoplasma capsulatum positive
15 lung histoplasmosis Histoplasma capsulatum positive
16 a, b skin histoplasmosis Histoplasma capsulatum positive
17 lung histoplasmosis negative positive
18 bone histoplasmosis negative positive
19 b, c intestine histoplasmosis negative positive
20 b, c intestine histoplasmosis negative positive
21 b oral mucosa histoplasmosis negative positive
22 lymph node histoplasmosis negative positive
23 lung histoplasmosis negative positive
24 lung histoplasmosis negative positive











25 lung histoplasmosis negative positive
26 lung histoplasmosis mixed sequence positive
27 a, b skin histoplasmosis negative positive
28 a, b skin histoplasmosis negative positive
29 a skin histoplasmosis negative positive
30 c intestine histoplasmosis Saccharomyces cerevisiae positive
31 intestine histoplasmosis Candida albicans positive
32 lung histoplasmosis negative negative
33 lung histoplasmosis negative negative
34 lung histoplasmosis Paracoccidioides spec. negative
35 lung histoplasmosis Paracoccidioides spec. negative
36 skin histoplasmosis Emergomyces spec. negative
37 brain blastomycosis mixed sequence negative
38 lung coccidioidomycosis Coccidioides spec. negative
39 lung coccidioidomycosis Coccidioides spec. negative
40 bone coccidioidomycosis Coccidioides spec. negative
41 lung coccidioidomycosis negative negative
42 unknown candidiasis Candida glabrata negative
43 unknown candidiasis Candida glabrata negative
44 unknown candidiasis Candida glabrata negative
45 unknown candidiasis Candida dubliniensis negative
46 unknown candidiasis Candida dubliniensis negative
47 intestine candidiasis negative negative
48 unknown candidiasis mixed sequence negative
49 unknown candidiasis Candida glabrata negative
50 paranasal sinus candidiasis Candida albicans negative
51 unknown candidiasis Candida albicans negative
52 unknown candidiasis mixed sequence negative
53 unknown candidiasis negative negative
54 unknown candidiasis negative negative
55 paranasal sinus candidiasis negative negative
56b unknown cryptococcosis Cryptococcus spec. negative
57 unknown cryptococcosis Cryptococcus spec. negative
58 unknown cryptococcosis Cryptococcus spec. negative
59 unknown hyphomycosis Aspergillus fumigatus negative
60 unknown hyphomycosis Aspergillus fumigatus negative
61 unknown hyphomycosis Aspergillus fumigatus negative
62 unknown hyphomycosis Aspergillus fumigatus negative
63 unknown hyphomycosis Aspergillus fumigatus negative
64 unknown hyphomycosis negative negative
65 a skin dermatophytosis Nannizzia gypsea negative
66 skin dermatophytosis Nannizzia gypsea negative
67 a, b skin dermatophytosis negative negative
a samples derived from animals, b inhibited samples, c samples from a patient with a culture-proven histoplasmosis.
In addition, 31 FFPE tissue specimens (human n = 29; animal n = 2) suggestive for other
fungal infections by histopathology were included (Table 2 and Figure 1) to analyze the clinical
specificity. If microscopy showed septated hyphae with acute angle branching, they were classified
as hyphomycosis [17]. Broad-based budding yeasts up to 10–15 µm were considered suggestive for
blastomycosis [17]. Histological evidence for cryptococcosis was defined as presence of narrow-based
budding yeasts (4–10 µm) with a thick capsule [17]. Spherules (10 to 100 µm in size) with multiple
endospores (2–5 µm) were defined as evidence for coccidioidomycosis [17]. For dermatophytosis,
the presence of septated hyphae within the stratum corneum was considered as suggestive [17].
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Candidiasis was considered when 3 to 5 µm in diameter yeasts were seen in the tissues, especially if
intermingled with pseudohyphae [17].J. Fung  2020, 6, x 6 of 12 
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emergomycosis: n = 1). Specific and broad-range PCR remained negative in two samples. ** Two 
were positive in the 28S qPCR, but sequencing showed mixed sequences. Histologically, both were 
suggestive for candidiasis. Five samples were negative in the 28S qPCR (histologically: blastomycosis 
(n = 1); coccidioidomycosis (n = 1), candidiasis (n = 3)). *** One was histologically a suspected 
aspergillosis and the other one a suspected dermatophytosis. 
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Figure 1. Formalin-fixed, paraffin-embedded tissue samples from patients with proven invasive fungal
infections used for diagnostic accuracy testing of qPCR assays. Samples are classified according to
the morphology of fungal elements by Grocott’s methenamine silver stain in tissue and results from
sequencing of the amplicon of a broad-range qPCR. * Broad-range PCR suggested alternative etiologic
agents in 3 suspected histoplasmosis samples (paracoccidioidomycosis: n = 2; emergomycosis: n = 1).
Specific and broad-range PCR remained negative in two samples. ** Two were positive in the 28S
qPCR, but sequencing showed mixed sequences. Histologically, both were suggestive for candidiasis.
Five samples were negative in the 28S qPCR (histologically: blastomycosis (n = 1); coccidioidomycosis
(n = 1), candidiasis (n = 3)). *** One was histologically a suspected aspergillosis and the other one a
suspected dermatophytosis.
2.4. Statistical Methods
Clinical sensitivity was defined as the percentage of positive results by the H. qPCR and by the
28S qPCR in the group of histologically suspected histoplasmosis with no alternative etiology detected
by the 28S qPCR (n = 33) and clinical specificity was defined as the percentage of negative results for
Histoplasma by the tested assays in the group of the other fungal infections, i.e., histopathology not
suggestive for histoplasmosis (Table 2) [24,29]. Proportions in groups were compared by Chi-squared
or Fisher’s exact test calculated in GraphPad Prism 7.04. A p < 0.05 in a two-sided test was considered
statistically significant.
3. Results
3.1. Analytical Sensitivity and Specificity
The probability to detect 1 fg/reaction of Histoplasma DNA standard in the H. qPCR, at least in
one sample of the duplicates, was 100%. Thus, 1 fg/reaction of Histoplasma DNA was defined as
the analytical sensitivity. If only duplicates were considered as positive, as described in the original
publication [23], the analytical sensitivity would have been 10 fg/reaction. This result is comparable
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with the results of the study of Simon et al. (analytical sensitivity = 50 fg of DNA per assay) [23].
The analytical specificity of the H. qPCR was 100%, as DNAs of other fungi were negative (Table 1).
3.2. Clinical Sensitivity and Specificity
No NTCs and extraction-negative controls were tested positive with the H. qPCR. Among the
36 histologically positive samples, seven samples (19%) were inhibited (animal origin: n = 4; human
origin: n = 3). Despite PCR inhibition, two of these were positive in both fungal qPCRs without
re-extraction (Nos. 4 and 16) (Table 2). Two were positive in the H. qPCR without re-extraction, and
remained negative in the 28S qPCR (Nos. 27 and 28). Three inhibited samples negative in both qPCRs
became positive in the H. qPCR and remained negative in the 28S qPCR after re-extraction (Nos.
19–21). The H. qPCR yielded positive results in 31 of 36 (86%) samples suggestive for histoplasmosis
by histopathology. In one of the negative samples, DNA of Emergomyces sp. (No. 36) and in two
samples DNA of Paracoccidioides sp. (Nos. 34, 35) were amplified by the 28S qPCR and identified by
sequencing (Figure 2). These samples were excluded from the clinical sensitivity analysis, leading to a
clinical sensitivity of 94% (31/33). The two remaining samples which were negative in the H. qPCR
also yielded a negative result in the 28S qPCR.
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The 28S q iti it of 48.5 (16/33) for the diagnosis of histoplasmo is.
Of the 33 i l s, 17 had a negative 28S qPCR result for Histoplasma in the presence of
a pos tive result in the H. qPCR. Thr e of these sevent en samples (i.e., 28S qPCR-negative but H.
qPCR-positi l fter 40 Ts i t e . qPCR, and of these, one showed a
double- siti ). This one belonged to a patient who was diagnosed also by culture.
Two showed only a single positive result (Nos. 23 and 24) and belonged to another patient. Hence, the
clini al sensitivity of the H. qPCR was significantly better than t e clinical sensitivity of the 28S qPCR
for diagnosing histoplasmosis from FFPE samples (31/33; 94% vs. 16/33; 48.5%; p-value < 0.0001).
Sequencing of the 28S qPCR amplicon in samples suggestive for histoplasmosis yielded a mixed
sequence in one sample (No. 26), Saccharomyces cerevisiae (No. 30) and Candida spec. (No. 31) in
another sample.
Of the 31 FFPE samples suggestive for other fungal infections by histopathology (candidiasis:
n = 14, hyphomycosis: n = 6, coccidioidomycosis: n = 4, cryptococcosis: n = 3, dermatomycosis; n = 3,
blastomycosis; n = 1), only two were inhibited (animal origin: n = 1; human origin: n = 1). One of these
became positive in the 28S qPCR after re-extraction (No. 56), the other one remained negative (No. 67).
All were negative in the H. qPCR. This leads to a diagnostic specificity of 100% for histoplasmosis.
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4. Discussion
We confirm the excellent analytical sensitivity and specificity of this previously published specific
qPCR targeting the ITS gene of Histoplasma. We demonstrated superior sensitivity of this assay
compared to a 28S qPCR from pathology blocks. However, this 28S qPCR identified alternative fungal
etiologies including the recently described emergomycosis. Therefore, the application of these PCR
assays on tissue samples may be a successful approach to amplify fungal DNA from pathology blocks
in order to identify the etiology of fungal infections suggestive for histoplasmosis by histopathology.
This may improve the management of individual cases and provide an alternative approach to define
endemic regions and the prevalence of histoplasmosis.
One explanation for the better performance of the specific qPCR could be a lower LOD of the
H. qPCR due to the difference in size of the amplicons (63 base pairs for the H. qPCR vs. 339 ± 7
for the 28S qPCR), which has also been proposed for other fungal infections [31]. The beneficial
effect of a shorter amplicon may be increased in FFPE samples in the context of DNA degradation
by formaldehyde [32]. If there is a mixed infection or concomitant colonization by other fungi, and
the amount of Histoplasma DNA is below the LOD in the 28S qPCR, this could be an explanation
for the preferential amplification of the DNA present in larger amounts, as Candida or Saccharomyces
(Nos. 30 and 31) in digestive samples.
There was no tissue sample suggestive for histoplasmosis which was tested negative in the H.
qPCR but from which Histoplasma DNA could be amplified by the broad-range assay, suggesting
that targeting the highly variable ITS region may not have impaired the sensitivity of this assay by
variation in primer or probe binding sites. However, 28S qPCR was able to identify alternative fungal
infections in three samples suggestive for histoplasmosis by histopathology (emergomycosis: n = 1;
paracoccidioidomycosis: n = 2) which were tested negative in the H. qPCR. Explanations for negative
results in the H. qPCR and in the 28S qPCR in two samples could be a DNA amount below the limit of
detection of both qPCRs.
Histoplasmosis in non-endemic regions may be diagnosed when lesions of the lung or other organs
are removed to exclude malignancy. Whether a positive H. qPCR in the presence of a histologically
suspected histoplasmosis in this scenario is a sign for an active Histoplasma infection, or if a negative H.
qPCR in the presence of a histologically suspected histoplasmosis is a sign for an inactive Histoplasma
infection, remains unclear.
Limitations of this study include, first, that it is a retrospective study with a potential for selection
bias, i.e., the clinical sensitivity of our assays may be lower in unselected samples. Second, the FFPE
samples with other fungal infections had been selected on the basis of prior identification. This is
the reason why we did not calculate an overall diagnostic sensitivity of the 28S qPCR. Third, only
three samples (Nos. 19, 20, and 30) of our dataset were from a patient with a culturally proven
Histoplasma infection.
There are only a limited number of publications about specific molecular diagnosis of Histoplasma
from FFPE samples [33–37], and only two that examine the clinical specificity with Histoplasma-negative
clinical FFPE samples [33,37]. A direct comparison of the analytical sensitivities of the different PCR
assays described is difficult, as quantifications were based on plasmid DNAs, genomic DNAs, or on
number of copies.
Our study of 67 FFPE samples is the largest examining both clinical sensitivity and clinical
specificity of a specific H. qPCR applied on clinical FFPE samples. Previously, a study compared
a nested PCR specific for Histoplasma (targeting the gene encoding a 100-kDa-like protein) with a
broad-range PCR followed by sequencing. Herein, four histologically suspected histoplasmosis samples
were analyzed. Of these, only one samples was positive for Histoplasma by broad-range fungal PCRs
(one PCR targeting the 18S rRNA and a PCR targeting the ITS-2 region), and the same sample was also
the only one positive in the specific Histoplasma nested PCR [37]. As in our study, the broad-range PCRs
identified an alternative fungal agent (Candida parapsilosis) in a sample suggestive for histoplasmosis
by histopathology [37]. Histoplasmosis is a fungal infection diagnosed in animals outside classically
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described endemic regions. In Europe, there have been several publications of Histoplasma infections in
wild (badgers, hedgehogs) and domesticated animals (cats, horses, dogs) [38–47], which point toward
a still-unknown reservoir in the environment of these animals. Furthermore, there have been two
publications suggesting autochthonous human histoplasmosis infections in several European states
such as Italy, Turkey, France, and Germany [48,49]. Whether histoplasmosis is an underestimated
health issue in Europe remains unclear, as diagnostics are seldom asked in samples from patients
without travel history.
In conclusion, using this specific H. qPCR on FFPE tissue samples helps to establish the diagnosis
of histoplasmosis, guiding patient care. In a larger context, the use of this assay on tissue blocks
may help to identify the prevalence of histoplasmosis in different regions, bringing further insights
to endemic regions and guiding public health interventions. Depending on the pretest probability
of histoplasmosis, the subsequent use in H. qPCR-negative samples or the additional use of this
broad-range fungal assay could be beneficial to identify alternative fungal etiologies that might not be
differentiated by histopathology, including emergomycosis, paracoccidioidomycosis and candidiasis.
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